Announcements Trials
Browse Landscape

Phase

Phase 1 18Phase 3 11Phase 1/2 7Phase 2 6Phase 2/3 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 8INDUSTRY 3UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × sintilimab × Clear all
NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Phase 2/3 Recruiting
680 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
668 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2/3 Unknown
595 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡